FDA Medical Device Labeling Requirements — A Manufacturer's Guide

What Is "Labeling" Under FDA Law?

The first thing most manufacturers get wrong is scope. FDA's definition of labeling is substantially broader than what you affix to the box.

Under 21 U.S.C. 321(m), labeling means all labels and other written, printed, or graphic matter upon any article or any of its containers or wrappers, or accompanying such article. Courts have interpreted "accompanying" broadly: material does not need to be physically in the box to qualify as labeling. A sales brochure sent to a physician before a device is shipped, a web page that describes the device's intended use, a promotional video shown at a medical conference — all of these can constitute labeling if they are associated with the device.

This distinction is operationally important. Your QMS should treat instructions for use, package inserts, the device manual, promotional materials, and your device's web presence all as labeling subject to FDA's requirements — not just the physical label on the device itself.

21 CFR Part 801: Required Label Elements

Part 801 of Title 21 of the Code of Federal Regulations is the primary regulation governing device labeling. It sets out what every device label must include and imposes requirements on prominence, placement, and language.

The following elements are required on the label of most medical devices:

Additional device-specific requirements may apply depending on device type — for example, requirements for radiation-emitting devices (21 CFR Part 1010), over-the-counter devices, or in vitro diagnostics.

Adequate Directions for Use

Of all the required label elements, adequate directions for use (ADFU) generates the most compliance questions. Section 801.5 defines it as directions under which a layperson can safely use the device for its intended purposes. The directions must cover intended uses, quantity, frequency, duration of administration, and any warnings that a typical user needs to avoid harm.

For most devices sold to the general public, full ADFU on the label or in a package insert is required. But many medical devices are intended only for use by or under the supervision of a licensed practitioner — a physician, dentist, or veterinarian. These devices can claim an exemption from the ADFU requirement under 21 CFR 801.109.

Getting the ADFU exemption wrong is a common source of misbranding findings. Even if a device qualifies, the labeling must still carry the Rx legend, and the device must not be sold directly to consumers. If FDA determines the exemption conditions are not met, the absence of ADFU makes the device misbranded per se.

Indications for Use and the Boundaries of Permitted Claims

The indications for use statement is the formal description of the disease or condition the device is intended to diagnose, cure, mitigate, treat, or prevent — along with the intended patient population. In a 510(k) submission, Section 10 captures this statement. For PMA devices, the approved labeling defines it. This statement is the blueprint for everything you may lawfully say about the device in labeling and advertising.

Manufacturers often assume that scientific evidence of a new use gives them permission to promote it. It does not. The cleared or approved indications define the permitted promotional scope, regardless of what the clinical literature shows. If a device was cleared to measure blood glucose, a manufacturer may not advertise it as a ketone monitoring device — even if a study supports that use — without first obtaining clearance or approval for that indication.

FDA's Office of Regulatory Affairs and Office of Prescription Drug Promotion (where device oversight overlaps with drug-device combinations) both monitor promotional materials for out-of-indication claims. Warning letters for off-label promotion in device advertising are publicly posted on FDA's website and are a useful reference for understanding where the line is drawn.

Off-Label Promotion and Misbranding Risk

Misbranding under 21 U.S.C. 352 occurs when a device's labeling is false or misleading in any particular, or when required elements are absent. Promotional claims that exceed the cleared or approved indications for use — even truthful claims supported by clinical data — can render a device misbranded.

The risk is not theoretical. FDA has issued warning letters to manufacturers for:

• Website claims describing uses not covered by the cleared indication
• Social media posts that imply the device treats conditions outside its approved scope
• Promotional videos, trade show presentations, and sales scripts referencing off-label uses
• Published case studies linked from the manufacturer's website that describe off-label applications

Medical device companies should conduct a labeling review before launching any promotional campaign, updating their website, or releasing new marketing collateral. The review should compare every claim — express or implied — against the cleared or approved indications for use and identify anything that could constitute an off-label promotion risk.

UDI Requirements on Device Labels

The FDA Unique Device Identification (UDI) rule, finalized in 2013 and implemented in phases through 2022, requires that most medical devices distributed in the United States carry a UDI on their label and, for implantable devices, on the device packaging.

A UDI has two components:

• Device Identifier (DI): A fixed portion specific to the labeler and the specific version or model of a device. This portion is the same across all units of a given model.
• Production Identifier (PI): A variable portion that conveys manufacturing information — lot or batch number, serial number, manufacturing date, expiration date, or distinct identification code — as applicable.

Labels must display the UDI in both human-readable interpretation (plain text) and in an automatic identification and data capture (AIDC) format. Barcode (1D or 2D data matrix) is the most common AIDC format for medical devices. The labeler must also submit device information to FDA's Global Unique Device Identification Database (GUDID), which is publicly accessible at accessgudid.nlm.nih.gov.

Certain device types are exempt from UDI requirements — including devices intended solely for export, custom devices, and some investigational devices — but exceptions are narrower than many manufacturers assume. If you are not certain your device qualifies for an exemption, it is worth reviewing the regulation and FDA's guidance before assuming you are out of scope.

IVD Labeling: Additional Requirements Under 21 CFR Part 809

In vitro diagnostic (IVD) devices are subject to additional labeling requirements under 21 CFR Part 809, which supplements the general device labeling requirements in Part 801. For IVDs, the package insert must include a range of technical details that standard device labels do not require.

Required IVD labeling elements under 21 CFR 809.10 include:

• Proprietary and established name of the product
• Intended use of the product
• Summary and explanation of the test
• Principles of the procedure
• Reagents, materials provided, and materials required but not provided
• Warnings and precautions
• Procedure — detailed step-by-step instructions
• Results section specifying expected values and performance characteristics
• Limitations of the procedure, including conditions that may affect results
• Specific performance characteristics — sensitivity, specificity, reproducibility, reference intervals

For laboratory-use-only IVDs (LUO), the label must carry the statement "For In Vitro Diagnostic Use" prominently. For home-use IVDs, directions must be adequate for a lay user, which often requires human factors testing to confirm usability.

Symbols in Device Labeling

FDA permits the use of symbols in device labeling as an alternative to written text, provided those symbols are recognized in a standard recognized by FDA — primarily ISO 15223-1 (Symbols to be used with information to be supplied by the manufacturer). FDA maintains a Symbols Database, and use of symbols from a recognized standard does not require a legend on the label itself, as long as the labeler meets the conditions in 21 CFR 801.15.

If a manufacturer wants to use a symbol that is not in an FDA-recognized standard, a legend identifying the symbol must appear on the label itself. When working with international standards, note that FDA's recognition of ISO 15223-1 was updated in 2016 — confirm the version of the standard FDA recognizes before selecting symbols from a newer edition.

Electronic Labeling (eIFU) and Digital Instructions for Use

FDA has issued guidance — and, for some device types, regulations — on when electronic instructions for use (eIFU) may substitute for paper labeling. The general principle is that paper labeling remains the default, but electronic alternatives can be permitted when certain conditions are met.

For devices that use software or have electronic displays, FDA's guidance on electronic labeling applies. Some device-specific product codes have associated special controls or guidance documents that address eIFU explicitly. For Class II devices seeking 510(k) clearance where eIFU is contemplated, this should be addressed in the 510(k) and, where applicable, in the indications for use and device description.

In the EU, the MDR introduced a regulatory pathway for eIFU under Regulation (EU) 207/2012 (now succeeded by later guidance). If you are preparing labeling for a device marketed in both the U.S. and EU, the requirements differ and must be addressed separately for each jurisdiction.

Frequently Asked Questions

What is the difference between a label and labeling?

A label is the physical display of written, printed, or graphic material affixed to or appearing on a device or its immediate container. Labeling is a broader term that includes any written, printed, or graphic material that accompanies the device — including package inserts, instructions for use, brochures, manuals, and promotional materials distributed with the device. A manufacturer's website, promotional videos, and sales aids can all constitute labeling if they are associated with the device and describe its intended use. The distinction matters because misbranding rules apply to all labeling, not only to the physical label.

Does every device need adequate directions for use on its label?

Most devices subject to 21 CFR Part 801 must bear adequate directions for use — instructions written for a layperson that enable safe and effective use of the device. However, prescription devices can qualify for an exemption under 21 CFR 801.109 if the device is sold only to or on the order of a licensed practitioner. Exempt prescription devices must still bear the legend 'Rx only' or 'Caution: Federal law restricts this device to sale by or on the order of a [physician/veterinarian],' and the device must meet other conditions. OTC devices generally must provide full directions for use because the end user is the general public.

When is off-label promotion considered misbranding?

Misbranding under 21 U.S.C. 352 occurs when a device's labeling makes claims that go beyond the intended use established at clearance or approval, or when required label elements are absent or false. Promoting a device for a use not covered by its cleared or approved indications for use — whether in advertising, promotional literature, sales scripts, or on a website — can constitute misbranding. The consequence is that the device is adulterated or misbranded in FDA's view, which can trigger warning letters, injunctions, seizure, or criminal prosecution. The indications for use statement from a 510(k) or PMA defines the permitted promotional scope.

What are UDI labeling requirements for medical devices?

The Unique Device Identification (UDI) system requires most medical devices distributed in the United States to carry a UDI on their label. The UDI consists of a Device Identifier (DI), which identifies the specific device version or model, and a Production Identifier (PI), which may include lot number, serial number, manufacturing date, or expiration date depending on the device. Labels must display the UDI in both a human-readable form (plain text) and an automatic identification and data capture (AIDC) format such as a barcode or 2D data matrix. Class III devices, life-supporting and life-sustaining devices, and implantable devices were phased in first; Class II and Class I devices followed. Device information must also be submitted to FDA's GUDID database.